Sutter Health to pay $13M for lab testing false claims
By 
Adrianne Appel2022-10-19T21:00:00
Sutter Health agreed to pay more than $13 million for violating the False Claims Act by billing the United States for toxicology tests it did not conduct but outsourced to other labs, the Department of Justice (DOJ) announced.
From August 2016 through June 2017, Sutter engaged in a laboratory services agreement with Navigant Network Alliance, in which Navigant sent urine specimens from physician offices and other laboratories nationwide to Sutter for testing. The DOJ alleged in its settlement agreement Sutter outsourced thousands of tests to third-party laboratories and still billed government health programs as if it had performed the tests at its own labs, a violation of the False Claims Act.
The DOJ alleged Sutter knowingly billed and was paid by the government programs for the tests it did not perform.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleCarter Healthcare, former execs to pay $30M in DOJ settlements over false claims
Home healthcare provider Carter Healthcare and its former chief executive officer and chief operations officer agreed to pay more than $30 million total under two settlements alleging the parties engaged in kickbacks to doctors and filed false claims.
-
ArticleDOJ intervenes in lawsuit against Cigna alleging Medicare fraud
Cigna created a home visit program for Medicare patients that artificially inflated government payments by intentionally incorrectly diagnosing tens of thousands of patients with serious illnesses, the Department of Justice charged in an intervenor complaint.
-
Article
DermaTran, other pharmacies settle with DOJ over pain cream false claims
DermaTran Health Solutions, its related pharmacy billing company, and three retail pharmacies agreed to pay more than $6.8 million to settle alleged violations of the False Claims Act for charging patients in federal health programs extra for pain relief creams.
More from Regulatory Enforcement
-
News BriefCFPB pullback signals further shift toward industry-friendly regulation
The U.S. Consumer Financial Protection Bureau continues to unravel amid pressure from Trump administration officials to shutter the agency. Not only has the agency informed its employees that it will no longer be a watchdog for the financial services industry, it has also laid off employees despite court orders blocking ...
-
News BriefTrump’s CFPB, dismissing Comerica case, continues to cut down Biden-era lawsuits
The Consumer Financial Protection Bureau dropped yet another consumer protection lawsuit against a bank or fintech provider since Donald Trump was sworn in as president in January. This time, it was with Comerica Bank.
-
News BriefCash App parent to pay $40 million for alleged BSA/AML violations in New York
Block Inc., maker of the popular Cash App, has been hit with a $40 million fine by New York for its alleged failure to report suspicious activity. The move marks the latest in a string of recent state and federal enforcement actions against the company.